Locally Activated Biologic Therapies for Selective Treatment of Chronic Sinonasal Disease

Abstract

Chronic sinonasal disease, including chronic rhinosinusitis (CRS) with or without nasal polyps, represents a substantial clinical challenge due to its multifactorial etiology and variable response to conventional medical and surgical therapy. The last decade has seen the advent of biologic agents targeting key inflammatory pathways implicated in disease pathogenesis. Recently, the focus has shifted toward the development and clinical implementation of locally activated biologic therapies designed for selective modulation of sinonasal mucosal inflammation, aiming to improve efficacy and minimize systemic exposure. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and conventional management of chronic sinonasal disease, with an emphasis on the mechanism, clinical application, and future scope of locally activated biologics. The article concludes with guideline-based recommendations and a critical appraisal of the clinical impact of these emerging therapies in otolaryngology practice.

Introduction

Chronic sinonasal disease is a prevalent inflammatory condition involving persistent inflammation of the nasal and paranasal sinus mucosa lasting 12 weeks or longer. The spectrum of disease, notably chronic rhinosinusitis (CRS), is heterogeneous, encompassing phenotypes with and without nasal polyposis. Conventional therapies, including intranasal corticosteroids, saline irrigations, antibiotics, and surgery, frequently fail to achieve sustained control in recalcitrant cases. In this context, targeted biologic therapies have emerged, offering novel mechanisms to address underlying immunopathologic drivers. Locally activated biologic agents, formulated for topical or site-specific delivery, promise enhanced selectivity, reduced systemic adverse events, and optimized patient outcomes. This review critically examines the evidence base for these innovative treatments and their potential to reshape current management paradigms.

Epidemiology / Disease Burden

Chronic sinonasal disease affects an estimated 12-16% of the adult population worldwide, exerting a considerable burden on quality of life, productivity, and healthcare systems. CRS accounts for a substantial proportion of outpatient otolaryngology visits and is associated with significant direct and indirect costs. Patients experience persistent nasal obstruction, rhinorrhea, facial pain or pressure, and in some cases, anosmia, which collectively impair daily functioning. The prevalence of CRS with nasal polyps (CRSwNP) is lower than that of CRS without nasal polyps (CRSsNP), but CRSwNP is more refractory, often requiring repeated interventions. The chronicity and recurrence of symptoms underscore the need for innovative, effective, and sustainable treatment modalities.

Pathophysiology

The pathogenesis of chronic sinonasal disease is complex and multifactorial, involving dysregulated innate and adaptive immune responses to environmental and microbial stimuli. CRS is broadly classified into T-helper 2 (Th2)-dominant and non-Th2 (Th1/Th17)-dominant endotypes. Th2-predominant inflammation, characterized by eosinophilia and elevated interleukins (IL-4, IL-5, IL-13), is particularly prominent in CRSwNP. This immune milieu promotes goblet cell hyperplasia, epithelial barrier dysfunction, and tissue remodeling leading to polyp formation. The identification of these molecular pathways has provided the rationale for targeted biologic interventions that modulate specific cytokines or immune cell activity within the sinonasal mucosa.

Risk Factors

Multiple risk factors contribute to the development and chronicity of sinonasal disease. Genetic susceptibility, atopy, asthma, nonsteroidal anti-inflammatory drug (NSAID) sensitivity, and environmental exposures such as tobacco smoke and occupational irritants have been implicated. Additionally, certain infections, immune deficiencies, and anatomical variations can predispose to persistent sinonasal inflammation. Understanding these risk factors is essential for individualized patient assessment and for identifying those who may benefit most from selective biologic therapies.

Clinical Features

Patients with chronic sinonasal disease typically present with a constellation of symptoms, including nasal congestion, anterior or posterior rhinorrhea, facial pressure or pain, and reduced sense of smell. Examination may reveal mucosal edema, purulent discharge, and, in the case of CRSwNP, visible polyps. Symptom severity and duration are key criteria for diagnosis. Persistent mucosal inflammation and its sequelae can lead to complications such as sleep disturbance, cognitive dysfunction, and exacerbation of comorbid asthma, reinforcing the importance of optimal disease control.

Diagnosis

The diagnosis of chronic sinonasal disease is primarily clinical, supported by endoscopic examination and imaging modalities such as computed tomography (CT) of the sinuses. Diagnostic criteria require symptoms lasting at least 12 weeks, confirmed by objective evidence of mucosal inflammation. Endotyping, based on biomarkers (e.g., tissue eosinophilia, specific cytokine profiles), is increasingly recognized as critical for guiding targeted therapy, including the selection of appropriate candidates for biologic interventions. Allergy testing and assessment for comorbid conditions are also integral to comprehensive evaluation.

Treatment & Management

Conventional management of chronic sinonasal disease includes saline irrigations, topical and systemic corticosteroids, antibiotics for acute exacerbations, and surgical intervention for refractory cases. Despite these approaches, a significant subset of patients remains symptomatic, highlighting the limitations of current treatments. Biologic therapies, initially developed for asthma and atopic conditions, have demonstrated efficacy in select CRS populations, particularly those with type 2 inflammation. These agents target key cytokines (e.g., IL-4, IL-5, IL-13) or their receptors, thereby attenuating eosinophilic inflammation and polyp formation. However, systemic biologics are associated with high cost and potential for systemic side effects.

Recent Advances / Emerging Therapies

Locally activated biologic therapies represent the next frontier in CRS management. These agents are engineered for topical or local delivery to the sinonasal mucosa, allowing for high local concentrations at the site of inflammation while minimizing systemic exposure. Strategies under investigation include intranasal delivery of monoclonal antibodies, nanoparticle-based platforms, and bioresponsive hydrogels that release biologics in response to local inflammatory cues. Early clinical trials have reported promising results, with significant reductions in polyp size, symptom burden, and mucosal eosinophilia. The pharmacokinetics, mucosal penetration, and immunogenicity profiles of these formulations are active areas of research. Local administration may also facilitate combination therapy and improve patient adherence.

Guideline Recommendations

Contemporary guidelines, including those from the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and the American Academy of Otolaryngology—Head and Neck Surgery, increasingly recognize the role of biologic therapies for severe, refractory CRS with type 2 inflammation. Recommendations emphasize careful patient selection, monitoring of response, and shared decision-making. While the majority of biologics in current use are administered systemically, ongoing research and clinical trials of locally delivered agents are likely to inform future guideline updates. Integration of endotyping and biomarker assessment is advocated to optimize therapeutic outcomes.

Conclusion

Locally activated biologic therapies offer a promising paradigm shift in the selective treatment of chronic sinonasal disease. By harnessing advances in targeted immunomodulation and innovative drug delivery, these approaches have the potential to improve clinical outcomes, reduce systemic adverse effects, and address unmet needs in patients with refractory disease. Ongoing clinical trials and translational research will further define their place in therapy. Careful integration of these emerging therapies into clinical practice, guided by evolving evidence and multidisciplinary collaboration, is essential for realizing their full benefit in sinonasal disease management.